Archives

Category Archive for: ‘Uncategorized’

  • How an Advisory Panel Could Lead to Increased Prescription Benefit Costs

    An advisory committee to the Department of Labor has just been tasked with studying whether pharmacy benefit managers should be required to disclose all sorts of competitive pricing information to their client employee health plans.  As readers of RxObserver know, this type of forced disclosure …

    Read More
  • Chris Jennings Returns as Advisor to RxObserver

    Last year we reported the sad (for us) news that longtime health policy expert Chris Jennings would be leaving RxObserver’s Advisory Board because he had been recruited by President Obama. Mr. Jennings has recently completed his service as Deputy Assistant to the President for Health …

    Read More
  • RxObserver Welcomes New Advisor – Professor Joanna Shepherd-Bailey

    RxObserver is pleased to welcome to its team of advisors Emory University Associate Professor of Law Joanna Shepherd-Bailey.  At Emory, Professor Shepherd-Bailey teaches Torts, Law and Economics, Analytical Methods for Lawyers and Statistics for Lawyers.  Much of Professor Shepherd-Bailey’s research focuses on topics in law …

    Read More
  • Departure News – Chris Jennings

    For the second time this year, President Obama has snatched into public service one of RxObserver’s advisors.  The New York Timesreported earlier this week that, “in an effort to put President Obama’s health care program back on track, the White House has recruited Chris Jennings, …

    Read More
  • Arrival & Departure Information

    RxObserver is pleased to announce a distinguished new addition to its Advisory Board and, as well, bid a reluctant farewell to a bright and engaging gentleman who is entering into public service. Joshua Wright, JD, Ph.D., Professor of Law at the George Mason University School …

    Read More
  • Seniors Spend Too Much on Medicare Part D

    According to a new study from the University of Pittsburgh, seniors are wasting hundreds of dollars annually on Medicare Part D prescription drug insurance coverage they don’t need. University researchers collected data in 2009 from 412,000 Part D enrollees. The results showed that only 5.2% …

    Read More
  • Generic Singulair Approved

    Singulair is a once-daily medication developed by Merck for the treatment of asthma and allergies. In the last quarter prior to the generic announcement, Singulair sales were $1.43 billion. This past August, the FDA announced that it had granted ten generic drug makers approval to …

    Read More
  • New Study Shows Impact of Shift to Generic Drugs in Holding Down Medical Costs

    A new study in Health Affairs provides additional evidence of how the switch from brand-name to generic drugs has helped to hold down overall health costs. According to the study by Peter J. Cunningham, a senior fellow and director of quantitative research at the Center for …

    Read More
  • Warfarin – Better Alternatives are Around the Corner

    For patients with atrial fibrillation, a common heart rhythm disorder, the risk of having a stroke is increased five-fold. Over 100,000 strokes per year or 10 to 15% of all strokes in the U.S. are the result of atrial fibrillation. Blood-thinning drugs which help prevent …

    Read More
  • Biosimilar (Generic) Version of Neupogen Approved by the FDA

    Most medications on the market today are chemically synthesized compounds. The approval process for generic versions of these chemical medications has been in place for close to 30 years. Starting in the 1980’s a new class of drugs – biotech drugs  – began appearing on …

    Read More
Page 1 of 212»